Form 4: Boston Scientific Executive Reports Stock Transactions

Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific, reported transactions involving restricted stock units and common stock.

Summary

• Arthur C. Butcher, an Executive Vice President and Group President at Boston Scientific, reported a transaction on May 2, 2026.
• This transaction involved the acquisition of 2,102 shares of common stock through restricted stock units (RSUs) with a reported value of $0.0000, indicating these were likely granted awards.
• Additionally, 1,007 shares of common stock were disposed of at a price of $56.50 per share.
• Following these transactions, Mr. Butcher beneficially owns 57,894 shares of common stock directly and an additional 20,228 shares indirectly through the company's 401(k) Retirement Savings Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions related to executive compensation and potential share sales, without significant positive or negative financial performance indicators.

Positives

• Acquisition of 2,102 shares of common stock via restricted stock units, indicating equity-based compensation.
• Continued indirect beneficial ownership of 20,228 shares through the 401(k) plan, showing long-term investment in the company.

Negatives

• Disposal of 1,007 shares of common stock at $56.50 per share, which could represent a sale.

Future Outlook

The filing indicates that shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, with the first anniversary of the date of grant. This implies a continued vesting and issuance schedule for restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported acquisition of RSUs aligns with common executive compensation practices in the medical technology sector, while the disposal of shares may reflect personal financial planning or diversification strategies by executives.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive may be interpreted by some shareholders as a signal, though the context of RSUs and 401(k) holdings suggests a broader picture of executive compensation and investment.
• Employees: The use of RSUs for executive compensation is a common practice that aligns executive interests with shareholder value.
• Management: The transactions reflect the ongoing compensation and equity management for key executives.

Next Steps

• Continued issuance of shares of common stock to the reporting person in four equal annual installments as per the RSU grant terms.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Common Stock, Executive Compensation, Beneficial Ownership